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Abstract
High-altitude exposure has been well recognized as a hypoxia exposure that significantly
affects cardiovascular function. However, the pathophysiologic adaptation of cardiovascu-
lar system to high-altitude hypoxia (HAH) varies remarkably. It may depend on the
exposed time and oxygen partial pressure in the altitude place. In short-term HAH,
cardiovascular adaptation is mainly characterized by functional alteration, including car-
diac functional adjustments, pulmonary vascular constriction, transient pulmonary hyper-
tension, and changes in cerebral blood flow (CBF). These changes may be explainedmainly
by ventilatory acclimatization and variation of autonomic nervous activity. In long-term
HAH, cardiovascular adaptation is mainly characterized by both functional and structural
alterations. These changes include right ventricle (RV) hypertrophy, persistent pulmonary
hypertension, lower CBF and reduced uteroplacental and fetal volumetric blood flows.
Keywords: high altitude, hypoxia, cardiovascular adaptation, compensatory and path-
ologic adaptation
1. Introduction
High-altitude environment exerts a unique challenge to human life, which is chiefly character-
ized by lower partial pressure of O2 (PO2) relative to sea level at the same latitudes. The
conventional definition of high-altitude hypoxia (HAH) is that arterial blood O2 saturation
(SaO2) in body measurably begins to fall at altitudes >2500 m [1]. It is one of the hypoxemic
types, which is due to a decrease in the amount of breathable oxygen caused by the low
atmospheric pressure of high altitudes, and in turn low maximal oxygen uptake (VO2 max),
and the arterial partial pressure of O2 (PaO2) in the body [2]. Reduced oxygen availability at
high altitude is associated with significant changes in cardiovascular function and increased
the risk of cardiovascular disease. Human body has both short-term and long-term adapta-
tions to altitude that allow it to partially compensate for the lowered amount of oxygen in the
atmosphere [3]. In this chapter we present the physiologic and pathologic adaptation of
cardiovascular system to short-term and long-term HAH and its underlying mechanisms.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Cardiovascular adaptation to high-altitude hypoxia
2.1. Cardiovascular adaptation to short-term high-altitude hypoxia
and the underlying mechanisms
With ascent to high altitude, there is a nonlinear decrease in barometric pressure and a reduction
in ambient partial pressure of oxygen (PO2), and, subsequently a decrease in the PO2 at every
point along the oxygen transport cascade from inspired air to the alveolar space, arterial blood,
the tissues, and venous blood. The higher the elevation attained, the greater the drop in PO2 in
the human body. These declines in oxygen tensions trigger a variety of physiologic responses in
the cardiovascular system over a period of minutes to weeks after the initial altitude hypoxia
exposure that enable the individual adapt to or compensate for the hypoxic environment.
At high altitude, in the short term, the low PO2 of inspired air will typically concomitantly
reduce SaO2, so a compensatory adjustment may immediately take place to meet the large and
consistent O2 demand of the aerobic metabolism of tissues and cells. Initial lack of oxygen is
sensed by the carotid bodies, which causes an increase in the breathing rate. Then the cardio-
vascular functions are changed in response to the short-term HAH.
2.1.1. Cardiac system
The main cardiac response to short-term HAH is the adjustment of cardiac function, which
includes the changes in heart rate (HR) and cardiac output, left ventricular ejection fraction (LVEF),
both ventricular systolic and diastolic function, and arterial blood pressure (ABP). At high altitude,
an initial response is that the heart beats faster. Cardiac contractility and submaximal cardiac
output also increase acutely during the first few days at altitude. This acute increase in cardiac
output may largely be explained by the increased heart rate and may be offset by reduced stroke
volume. For example, an earlier study demonstrated that acutely breathing an inspired fraction of
O2 of 0.12 caused 22% increase in cardiac output accompanied with 18% increase in heart rate and
unchanged stroke volume, so the oxygen delivery to the tissues remained unchanged [4]. In
addition, an evaluation of ventricular functions by Doppler echocardiography with tissue Doppler
imaging (TDI) in volunteers exposed to acutely short-term (90 min) HAH reported that short-term
HAH significantly increased HR, LVEF, isovolumic contraction wave velocity (ICV), acceleration
(ICA), and systolic ejection wave velocity at the mitral annulus, indicating enhanced left ventricu-
lar systolic function. However, there was no change in right ventricular area shortening fraction,
tricuspid annular plane systolic excursion (TAPSE), ICV, and ICA at the tricuspid annulus, dem-
onstrating preserved right ventricular systolic function. Furthermore, increase in isovolumic relax-
ation time (IRT) at both annuli indicated altered diastolic function of both ventricles [5].
In response to a short-term high-altitude exposure, blood pressure is likely increased to a
variable extent in many individuals. The changes in blood pressure may be dependent on
individual conditions, the absolute altitude of exposure, and the duration of stay at altitude. A
recent study has reported that after acute exposure to 3700 m, diastolic blood pressure and
mean arterial blood pressure rose gradually and continually in healthy male young adults [6].
Further analysis showed that higher blood pressure accompanied poor sleeping quality and
higher incidence of acute mountain sickness. In addition, systolic blood pressure also
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significantly increased after high-altitude exercise [6]. Significant rise in systolic and diastolic
blood pressure in the initial phase of exposure to altitude was also reported in other studies [7, 8].
There are several possible mechanisms involved in short-term HAH-mediated cardiac dys-
function. One of the important mechanisms is the changes of autonomic nervous system
including parasympathetic nervous system and sympathetic nervous system (SNS). A func-
tional approach to assess the role of parasympathetic nerves by muscarinic blockade reported
that tachycardia after 8 hours of exposure to hypoxia can be prevented by muscarinic block-
ade, which indicated that a muscarinic effect was involved in the tachycardia after short-term
HAH [9]. Acute exposure to high altitude induced a statistically significant increase in heart
rate associated with a shift of sympathovagal balance towards more sympathetic and less
parasympathetic activity, which suggests a depression of autonomic functions and a relative
increase in sympathetic activity at higher hypoxic levels [10]. These adaptations consist of
significantly increased sympathetic activation as evidenced by heightened circulating catechol-
amine levels (such as norepinephrine) [11–14]. Mazzeo et al. reported a different catecholamine
response between acute and chronic high-altitude exposure [13]. In response to acute exposure
to 4300 m (4 hours), the arterial plasma epinephrine levels but not norepinephrine levels were
significantly increased. However, both epinephrine and norepinephrine concentrations were
increased after 21 days of chronic exposure [13]. These findings provide evidence for a differ-
ential adaptive response between sympathetic neural activity and that of the adrenal medulla
during high-altitude exposure.
The increase in sympathetic tone may be a natural response by acute nonadapted subjects to
counteract the effects of hypoxia. Indeed, short-term altitude exposure can directly or indi-
rectly affect the vascular tone of systemic resistance vessels and enhances ventilation and
sympathetic activity through the activation of peripheral chemoreceptors [15]. The peripheral
chemoreceptors mainly include carotid bodies and aortic chemoreceptor, which are served as
hypoxia sensors in the arterial walls. Carotid bodies act as sensitive monitors of arterial O2
tension (PaO2), whereas aortic chemoreceptors mainly monitor arterial O2 content (CaO2). So,
carotid bodies evoke stronger respiratory responses than aortic chemoreceptors [16]. A study
in humans exposed to hypoxia demonstrated that carotid bodies are chiefly responsible for
ventilatory and vascular response, whereas aortic chemoreceptors mainly mediated the
tachycardic response [17]. Another study indicated that hyperventilation induced by hypoxic
stimulation of carotid bodies decreased vagal traffic to the heart through Hering-Breuer reflex,
which plays an important indirect role in tachycardic response to hypoxia [18]. Meanwhile,
hypoxic stimulation of carotid bodies also directly activated SNS to accelerate HR through
increasing circulating catecholamine [19]. In addition, hypoxic activation of peripheral chemo-
receptors was addressed to reset the baroreflex control of both HR and sympathetic nervous
system (SNS) activity to higher levels, so that HR and sympathetic vasoconstriction were
increased, which were independent of breathing rate and tidal volume [20].
2.1.2. Pulmonary vascular system
Pulmonary circulation is the important portion of the cardiovascular system responsible for the
gas exchange. Short-term HAH can immediately trigger hypoxic pulmonary vasoconstriction
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(HPV), which, in conjunction with increased cardiac output, leads to an enhanced pulmonary
vascular resistance and a rise in pulmonary artery pressure. An investigation reported that human
pulmonary vascular tone rose rapidly to reach a maximum within 5 min and was then
maintained for the duration of the altitude exposure. This acute hypoxic pulmonary vasoconstric-
tion (HPV) was reversed to baseline values within 5 min after breathing oxygen [21]. HPV is
intrinsic to the pulmonary vascular smooth cells and independent of the endothelium, as demon-
strated in experiments with endothelium-denuded pulmonary arteries (PAs) [22]. In short-term
HAH, it was confirmed that small resistance pulmonary arteries (<200 μm) were highly sensitive
to the alveolar O2 tension. There is a functional “O2-sensing unit” in the pulmonary artery smooth
muscle cell (PASMC) mitochondria, which can detect falls in alveolar O2, leading to produce a
mediator to modulate the function of effector proteins. During hypoxia, the production of the
mediator is low, which causes the inhibition of specific O2-sensitive K
+ channels resulting in
depolarization of PASMCs and activation of voltage-gated L-type Ca2+ channels. Ca2+ influx is
thereby increased and cytosolic Ca2+ elevated, resulting in activation of the PASMCs’ contractile
machinery and development of HPV [23]. Given the fact that there is a lack of voltage-gated L-
type Ca2+ channels in endothelium, it is most likely that HPV is endothelium-independent and
intrinsic to pulmonary smooth muscle cells. However, endothelium-dependent and -independent
mechanisms could modulate this response. Hypoxia may enhance pulmonary artery resistance
through endothelin (ET) and sympathetic stimulation, whereas HPV may be attenuated by
increased release of NO, hyperventilation improving alveolar PO2, and respiratory alkalosis [24].
High-altitude pulmonary edema (HAPE) is not an uncommon form of acute altitude illness that
occurs in otherwise healthy mountaineers at altitudes typically above 2500 m. The initial cause of
HAPE is a shortage of oxygen caused by the lower air pressure at high altitudes. The mecha-
nisms underlying this oxygen shortage-induced HAPE are poorly understood, but one of the
critical mechanisms is an excessive rise in pulmonary vascular resistance or hypoxic pulmonary
vasoconstriction leading to increased microvascular pressures. This enhanced hydrostatic stress
causes dynamic changes in the permeability of the alveolar capillary barrier and induces a high-
permeability noninflammatory lung edema. Previous report indicated that decreased nitric oxide
release and enhanced endothelin levels following acute high-altitude exposure may be the major
determinants of exaggerated hypoxic pulmonary vasoconstriction in HAPE-susceptible individ-
uals [25]. In addition, other hypoxia-mediated changes of sympathetic nervous activity, endothe-
lial function, and altered levels of other vasoactive mediators such as endothelin and angiotensin
II may also contribute additionally to HAPE susceptibility. Although higher pulmonary arterial
pressure is associated with the development of HAPE, pulmonary hypertension may not in itself
be sufficient to explain the development of high-altitude pulmonary edema. Development of
pulmonary hypertension can occur in the absence of HAPE in humans at high altitude.
2.1.3. Cerebrovascular system
The brain is the most oxygen-dependent organ in the body. In response to acute exposure to
high altitude, cerebral blood flow (CBF) rises significantly to ensure an adequate supply of O2
to meet the brain tissues’ large and consistent demand [26–28]. The mechanisms underlying
the regulation of CBF during short-term HAH are complex and depend partly on the degree of
hypoxia per se and on the partial pressures of arterial oxygen (PaO2) and arterial carbon
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dioxide (PaCO2) [29]. Upon ascent to high altitude, a severe drop in PaO2 (to <40–45 mmHg)
induces a cerebral vasodilation, which suggests that altitude-mediated reduced PaO2 may act
as a cerebral vasodilator. However, the fall in PaCO2 following hyperventilation caused by
hypoxic-induced activation of peripheral chemoreceptor also produces cerebral vasoconstric-
tion. Therefore, the changes in CBF at high altitude are highly related to the balance of PaO2/
PaCO2 in the circulation. Indeed, it has been demonstrated that the low PaO2-to-PaCO2 ratio
explains 40% of the increase in brain blood flow upon arrival at high altitude (5050 m) [26]. The
increased CBF is mainly due to heightened hypoxic-induced dilatation in the cerebral circula-
tion prior to ventilatory adjustments [26]. A number of mechanisms are proposed to contribute
to the cerebral vasodilation. One of the mechanisms is that hypoxia may increase adenosine
and nitric oxide level, which causes an increase in arterial diameter [27]. In addition, the
cerebral dilatation can be also regulated through other factors (such as hypoxia inducible
factor). Furthermore, the fact that acute altitude exposure-mediated increased CBF and cere-
bral vasodilation can be reversed by supplemental oxygen suggests a direct hypoxic effect.
With increasing altitude, increased CBF is believed to be one compensatory mechanism serv-
ing to maintain normal oxygen flux to the brain in the face of arterial hypoxemia. However, the
profound hypoxemia experienced by climbers at extreme altitude (>5500 m) is known to be
related with cerebral dysfunction. Previous investigation has shown that hypoxia-mediated
cerebral vascular dysfunction and cerebral edema is one of the major cause of deaths over 8000
m on Everest [30].
High-altitude cerebral edema (HACE) is a medical condition in which the brain swells with
fluid because of ascending to a high altitude. It occurs when the body fails to acclimatize while
ascending to a high altitude. HACE can be prevented by ascending to heights slowly to allow
the body more time to acclimatize. The major cause of HACE is oxygen deprivation. It is most
often a complication of acute mountain sickness or high-altitude pulmonary edema. The
current leading theory of its pathophysiology is that HACE is likely a result of vasogenic
edema [31]. High-altitude hypoxia increases vascular permeability, which passes through the
vasogenic endothelium in the brain. The leaking may be caused by increased pressure, or it
may be caused by inflammation that makes the endothelium vulnerable to leaking. It has been
reported that activation of vascular endothelial growth factor (VEGF) by hypoxia-inducible
factor may be one of the major causes leading to overperfusion of microvascular beds, endo-
thelial leakage, and hence edema [31]. In addition, high-altitude hypoxia can alter cerebral
vasodilation coupled with a possible impairment of the autoregulation of cerebral blood flow
and disruption of the integrity of the blood brain barrier possibly by hypoxia-mediated release
of certain neuromodulators such as VEGF and calcitonin gene-related peptide (CGRP). Fur-
thermore, the increased sympathetic nervous activity at high altitude may also play a role in
the development of cerebral edema.
2.2. Cardiovascular adaptation to long-term HAH and the underlying mechanisms
Acute short-term exposure to high altitude has been recognized as a type of cardiovascular
stress, and results in an immediate increase in heart rate, cardiac output, and a transient rise in
the blood pressure but without significant changes in the ejection fraction. However, long-term
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exposure to high altitude or people who reside at high altitude show compensate change in
cardiovascular system that has allowed them to adapt to high-altitude chronic hypoxia.
2.2.1. Cardiac system
In long-term HAH, the changes in cardiac function are different from those in acute short-term
HAH. Similar to the short-term HAH, heart rate and arterial blood pressure may remain
increased, but stroke volume is decreased and the cardiac output returns to baseline after a
longer hypoxic exposure [4]. In long-term HAH, the heart must preserve adequate contractile
function in spite of lowered oxygen tension in the cardiac circulation. Suarez et al. had conducted
studies in young men during acclimation to a simulated altitude in a chamber for 40 days and
their results showed that left ventricular systolic function indices including ejection fraction, ratio
of peak systolic pressure to end systolic volume, and mean normalized systolic ejection rate at
rest and exercise, were sustained in all subjects at high altitude despite reduced preload, pulmo-
nary hypertension and severe hypoxemia, which means remarkably preserved contractility and
excellent tolerance of the normal myocardium to long-term HAH [32]. Another study also
demonstrated that cardiac contractility remained normal during exposure to altitude-induced
hypoxia with preservation of LV ejection fraction and LV percent fractional shortening [33].
Cardiac adaptation to long-term HAH is characterized by a variety of functional adjustments
to maintain homeostasis with minimum expenditure of energy. Such adjustments may help to
protect the heart from development of ischemic heart disease. An epidemiological study
reported that men residing at high altitude resulted in protection against death from ischemic
heart disease [34]. The epidemiological observations on the cardioprotective effect of high
altitude were confirmed in various experimental models [35–37]. It has been reported that the
hearts of animals adapted to long-term HAH develop better functional recovery following
ischemia and produce smaller cardiac infarction. In addition, it has also been reported that
adaptation to HAH could protect the heart against ischemia-induced arrhythmias [38]. How-
ever, the cardioprotective effect of adaptation to HAH is age-dependent. For example, a recent
experiment with rats at stimulated altitude of 5000 m from 7-week-old to their entire lifetime
[39] showed that cardiac tolerance to acute hypoxia was significantly increased in up to 18
months-old rats, but it was lost in senescent rats (25 months-old). Similarly, people living at
high altitude in the Andeans lost their adaptation and have higher incidence of pulmonary
hypertension in their aged life.
The mechanisms underlying cardiac functional changes in response to long-term HAH remain
far from being understood. However, recent studies in animals and man have highlighted the
role of both sympathetic and parasympathetic nervous system in cardiac adaptation following
long-term HAH. The role of the parasympathetic system in regulation of heart rate has been
examined in humans from the response to muscarinic blockade. A study in human after
exposing to an altitude of 5260 m for 9 weeks found that muscarinic blockade increased HR
both at rest and during exercise, which suggested that enhanced parasympathetic activity
involves in the altered HR during long-term HAH [40]. Meanwhile, another study in animals
reported that the muscarinic receptor density in animals native to high altitude was signifi-
cantly higher than in those living at low altitude. After 5 weeks of relocation to sea level the
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muscarinic receptor density concomitantly declined to the level in sea level animals [41]. In
addition, similar to the short-term HAH, the sympathetic nervous system also plays a key role
in the regulation of HR and cardiac function during long-term HAH, but the pattern is
different from those in short-term HAH. Previous studies in long-term HAH subjects reported
that plasma norepinephrine level increased more significantly than epinephrine levels [13, 14,
42, 43]. Although the resting heart rate remains increased, the maximal heart rate (the heart
rate at maximal exercise) is reduced at long-term HAH. In view of the evidence of elevated
systemic catecholamine levels after long-term HAH, the lower maximal heart rate suggests a
change in adrenergic receptor density. Indeed, several studies in animals have shown the
change in adrenergic receptor density in response to long-term HAH. For example, a study in
rats exposed to 21 days of hypobaric hypoxia found that there was a significant reduction in β-
adrenergic receptor density [44]. Another study in rats following 21 days of exposure to a
simulated altitude of 5500 m also reported a downregulation of α- and β-adrenergic receptor
density in ventricular tissues [45]. Furthermore, studies in humans using isoprenaline as an
indirect measure of density of β-adrenergic receptors demonstrated a downregulation of β-
adrenergic receptors at high altitude [46]. It has been reported that prolonged HAH exposure
could also alter peripheral and central adrenergic receptor expression, leading to changes in
cardiac function [47, 48]. Taken together, sustained long-term HAH exposure causes progres-
sive enhancement of both sympathetic and parasympathetic activity, resulting in alteration of
cardiovascular function.
In addition to cardiac functional adaptation, cardiac structural adaptation also occurs follow-
ing long-term HAH exposure. One of the changes in response to sustained HAH is develop-
ment of right ventricle (RV) hypertrophy. Long-term high altitude-induced RV hypertrophy is
a beneficial adaptation that helps to counteract the increased afterload caused by persistent
pulmonary hypertension and maintain a normal cardiac output [49]. During the compensated
phase of hypertrophy, a study using an isolated preparation of the RV working heart demon-
strated that mechanical performance was almost doubled compared with the control group,
while the index of contractility remained unchanged, which means that the elevated ventricu-
lar performance is merely the result of the increased muscle mass. Meantime, the markedly
improved ability of the RV maintaining cardiac output against increased pulmonary resistance
was observed [49]. Hypertrophic RV is associated with significant changes of cardiac protein
profiling [50]. Experimental results in rats exposed to intermittent high-altitude hypoxia have
shown that the concentration of collagenous and noncollagenous proteins was significantly
increased both in hypertrophic RV and nonhypertrophic LV [51]. Cardiac enlargement may be
the result of both an increase in the number of individual cell elements (hyperplasia) and an
increase in their volume (hypertrophy).
2.2.2. Pulmonary vascular system
The most common effect of long-term sustained HAH exposure is the development of pulmo-
nary hypertension. Previous studies have reported a prevalence of high-altitude pulmonary
hypertension between 5% and 18% of the population living at high altitude [52]. High-altitude
pulmonary hypertension is characterized by increased pulmonary vascular resistance secondary
to hypoxia-induced pulmonary vasoconstriction and vascular remodeling. The pulmonary
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vascular adaptations involve all elements of the vessel wall and include endothelial dysfunction,
extension of smooth muscle into previously nonmuscular vessels and adventitial thickening.
Long-term high-altitude-induced pulmonary hypertension was not completely reversed by oxy-
gen breathing, suggesting that pulmonary arteries structural remodeling plays a pivotal role in
pulmonary hypertension during long-term HAH [53]. Pulmonary arteries (PAs) remodeling
involves cellular hypertrophy and hyperplasia in all three structural layers of PAs, namely
adventitia, media, and intima. In addition, long-term HAH also causes other structural changes,
such as the migration of medial smooth muscle cells (SMCs) into the intima, fibroblast prolifer-
ation and increased collagen deposition in the adventitia, more extracellular matrix proteins
secreted by endothelial cells, and the appearance of SM-like cells in previously nonmuscularized
vessels of the alveolar wall. All these changes eventually result in a reduction of the vascular
lumen diameter and an increase in pulmonary vascular resistance [54].
The molecular mechanisms underlying the pathogenesis of high altitude-induced pulmonary
hypertension are not fully understood, but several hypoxia-mediated signaling pathways are
thought to play a key role. In the pulmonary vasculature, some membrane-bound receptors and
signaling proteins are sensitive to hypoxia and play important role in the vascular medial
proliferation. For example, a recent study in a sheep model of in utero high-altitude long-term
hypoxia exposure demonstrated pulmonary vascular remodeling similar to that seen in other
animal models of pulmonary hypertension [55]. The results indicated that pulmonary arteries of
long-term HAH-exposed fetuses exhibited medial wall thickening and distal muscularization
associated with an increased epidermal growth factor receptor (EGFR) protein expression in the
pulmonary arteries. Furthermore, it has been demonstrated that the proliferation of fetal ovine
pulmonary vascular smooth muscle cell was attenuated by inhibition of EGFR with a specific
EGFR protein tyrosine kinase inhibitor [55]. These findings suggest that EGFR plays a role in
fetal ovine pulmonary vascular remodeling following long-term HAH and that inhibition of
EGFR signaling may reverse high altitude-induced pulmonary vascular remodeling. Similar to
EGFR, platelet-activating factor (PAF) and PAF receptor have also been implicated in the
pathogenesis of long-term HAH-induced pulmonary remodeling and hypertension in different
animal models [56, 57]. In those studies, high PAF and PAF receptor expression levels in the
pulmonary arteries have been reported in the long-term hypoxia-exposed animals [56, 57].
Furthermore, PAF receptor antagonists attenuated hypoxia-induced pulmonary hypertension
and pulmonary vascular remodeling [56], suggesting that PAF receptor-mediated signaling also
plays a key role in pulmonary vascular remodeling.
Accumulating evidence indicates that intrinsic changes in the ionic balance and calcium
homeostasis of pulmonary arterial smooth muscle cells (PASMCs) caused by long-term hypoxia
have a profound effect on PA remodeling. The membrane depolarization of PASMCs following
the hypoxic inhibition of O2 sensitive K
+ channels activated Ca2+ influx and elevated cytoplas-
mic ionized Ca2+ via voltage-gated Ca2+ channels. Changes in the transport of K+ and Ca2+
through their respective ion channels modulate these processes by affecting cell volume, mem-
brane potential, gene transcription, apoptosis, and cell-cycle progression. The adaptation of
these ion channels at high altitude appears to involve in pulmonary arteries remodeling [58].
Although PASMCs are the major components of arteries that actively involve long-term HAH-
mediated sustained vasoconstriction and enhanced medial hypertrophy, endothelial cells, on
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the other hand, can sense humoral and hemodynamic changes incurred by high-altitude
hypoxia, triggering their production of vasoactive and mitogenic factors that then affect
PASMCs’ function and growth [54, 59, 60]. Endothelin (ET)-1 is an important mediator of
hypoxia-induced pulmonary vasoconstriction and vascular remodeling [61]. Chronic hypoxia
increases ET-1 gene transcription and peptide synthesis in cultured endothelial cells. ET-1 and
its receptors are selectively upregulated in patients with primary pulmonary hypertension and
in humans exposed to high altitude [61]. Rats exposed to chronic hypoxia exhibit increased
pulmonary artery pressure associated with an increase in ET-1 peptide levels. Moreover,
hypoxic pulmonary vascular remodeling can be prevented and reversed by administration of
ET receptor antagonist [61], suggesting a key role of ET-1 and its receptor-mediated signaling
in chronic hypoxia-induced pulmonary hypertension and vascular remodeling.
2.2.3. Cerebrovascular system
Upon ascent to high altitude, cerebral blood flow (CBF) rises substantially. However, as HAH-
exposed time is increased, the increased CBF will return to near sea level values within 1–3
weeks, which displays clear time-dependent changes during acclimatization. In general, high-
altitude native residents have lower CBF values compared to sea level natives. The major
mechanism underlying the reduction in CBF of high-altitude residents is the reported elevation
in hematocrit and consequently increased arterial oxygen content (CaO2), suggesting an
inverse relationship between CBF and CaO2. There are at least four reflex mechanisms that
regulate CBF: (1) hypoxic ventilator response; (2) hypercapnic ventilatory response; (3) hyp-
oxic cerebral vasodilation; and (4) hypocapnic cerebral vasoconstriction [62]. On initial arrival
at high altitude, hypobaric hypoxia changes the mediators of CBF because of a decrease in
arterial oxygen tension, which is an independent mediator of cerebral arteriolar dilatation. In
addition, hypoxemia can trigger hyperventilation associated decrease in arterial carbon diox-
ide tension, which will cause cerebral arterial constriction because of an associated increase in
periarteriolar pH. Therefore, over a few days period at a constant altitude, the influence of the
arterial oxygen tension-induced threshold for cerebral vasodilation is attenuated and the
degree of hypocapnia is enhanced. Furthermore, during a prolonged stay at altitude, the
hematocrit also increases, resulting in an increased arterial oxygen content at an unchanged
oxygen tension. This change will tend to decrease CBF. Therefore, cerebral hemodynamics
during acclimatization to altitude is the result of these homeostatic mechanisms. In addition
to these reflex responses, CBF is also regulated by some other hypoxia-induced changes. For
example, high-altitude hypoxia-induced changes of cerebral capillary density, hypoxia-
induced factor (HIF), nitric oxide, endothelin-1, reactive oxygen species (ROS), and neuro-
transmitters may be responsible for the falling CBF during long-term HAH [29].
2.2.4. Uteroplacental vascular system
Pregnancy is associated with a significant increase in uterine blood flow that optimizes the
delivery of oxygen and nutrients to the developing fetus. The greater fall in uteroplacental
vascular resistance preferentially directs blood flow to this vascular bed, raising the uterine
blood flow from 20–50 ml/min in the nonpregnant state to 450–800 ml/min in the near-term
pregnant stage [63]. The adaptations in the uterine circulation to pregnancy are complex and
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are mainly achieved through the remodeling of uterine vasculature, enhanced vasodilator
response, blunted vasoconstrictor response, and reduced pressure-dependent myogenic
reactivity. At sea level pregnant uterine artery diameter doubles due to the vascular growth
and remodeling as well as due to alterations in vasoreactivity, and changes in the active and
passive properties of the uterine artery vascular wall. The molecular mechanisms prompting
uterine vascular growth and enlargement of the vascular diameter are not fully understood.
However, one of the major mechanisms underlying pregnancy-mediated decreased uterine
vascular resistance may be regulated through hormonal stimuli. It has been reported that
estradiol is likely a key player because of its angiogenic properties and stimulatory effects on
nitric oxide-mediated vasodilation [64]. Estrogen receptors (ERs) have been identified in
uterine artery vascular smooth muscle and their expressions are significantly increased in
pregnant uterine arteries as compared with nonpregnant uterine arteries [65]. The preg-
nancy-associated increased ER expression may directly upregulate vascular endothelial
growth factor (VEGF), MAP kinase, and eNOS expression and their activities, leading to
promote uterine vascular growth and vasodilation [65]. The decreased uterine vascular
resistance can also be regulated by contractile agonists or related proteins. For example,
pregnancy decreases PKC activity but increases ERK kinase activity in uterine arteries,
leading to decrease in uterine artery contractility [66, 67]. In addition, myogenic tone and
distensibility are additional factors that can alter uterine arterial intraluminal diameter and
uterine vascular resistance. It has been reported that pregnancy significantly downregulates
pressure-dependent myogenic tone and increases the pressure-dependent passive uterine
arterial diameter. The reduced myogenic tone is mediated by an increase in the inhibitory
effect of ERK and a decrease in the PKC signal pathway [68].
High-altitude hypoxia has profound effects on uteroplacental circulation including altered
uteroplacental and fetal volumetric blood flows, resulting in fetal intrauterine growth restric-
tion. It has been demonstrated that high-altitude hypoxia decreases the pregnancy-associ-
ated rise in uterine blood flow [69]. Reduced uterine blood flow and inadequate perfusion of
the placenta have been attributed to the increased incidence of preeclampsia and fetal intra-
uterine growth restriction [1]. One of the mechanisms that contributes to the decreased
uterine blood flow may be a significant inhibition of pregnancy-associated increase in uterine
vascular growth. It has been reported that there is only half as much pregnancy-mediated
increase in uterine arterial DNA synthesis in chronic hypoxic vs. normoxic animals [70]. The
proliferative response to serum stimulation in cultured uterine arterial smooth muscle cells is
also attenuated by hypoxia exposure [70]. In addition, high-altitude hypoxia also can alter
pregnancy-associated responses to contractile proteins and vasodilator-mediated signaling
pathways. Experimental studies in sheep, that experienced long-term high-altitude exposure
during pregnancy, showed significant increase in the pressure-dependent myogenic tone of
resistance-sized uterine arteries by suppressing the ERK1/2 activity and increasing the PKC
signaling pathway [65]. Furthermore, high-altitude hypoxia exposure selectively
downregulated estrogen-α receptor expression in uterine arteries of pregnant animals and
inhibited the steroid hormone-mediated adaptation of ERK1/2 and PKC signaling pathways
to cause an increase in the myogenic tone of uterine arteries in pregnancy [65]. These obser-
vations provide a novel molecular mechanism underlying high altitude-induced decrease in
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uterine blood flow by inhibition of estrogen/receptor-mediated signaling in pregnancy. The
large-conductance Ca2+-activated K+ (BKca) is abundantly expressed in vascular smooth
muscle cells. Previous studies have suggested that BKca channel is involved in the regulation
of uterine circulation and the increase in uterine blood flow during pregnancy [71]. The BKca
channel in vascular smooth muscle is a major effector in response to hypoxia. Studies in
pregnant sheep model of long-term high-altitude (3801 m) exposure provide novel evidence
that long-term high-altitude hypoxia during pregnancy adversely affects the uterine circula-
tion via downregulating BKca channel function in uterine vasculatures [72]. High-altitude
hypoxia during gestation significantly inhibited pregnancy-associated upregulation of BKca
channel activity and attenuated BKca channel current density in pregnant uterine arteries
[72]. This was mediated by a selective downregulation of BKca channel β1 subunit expres-
sion in the uterine arteries. In accordance, high-altitude hypoxia impaired the role of the
BKca channel in regulating pressure-induced myogenic tone of uterine arteries that was
enhanced in pregnant animals acclimatized to high altitude. These results suggest that
selectively targeting BKca channel may be another key mechanism in the maladaptation of
uteroplacental circulation caused by high-altitude hypoxia, which may contribute to the
decreased uterine blood flow and fetal intrauterine growth restriction associated with mater-
nal hypoxia. The molecular mechanisms underlying high-altitude hypoxia-mediated alter-
ation of targeting gene expression in pregnant uterine arteries are not completely
understood. However, recent studies suggest that epigenetic mechanism plays an important
role in regulation of gene expression in adaptation to high altitude [73]. The results showed
that chronic hypoxia increased estrogen receptor α subunit (ER-α) promoter DNA methyla-
tion at both specific protein-1 and upstream stimulatory factor binding sites, decreased
specificity protein-1 and upstream stimulatory factor binding to the promoter, and
suppressed ER-α expression in uterine arteries of pregnant animals [73]. Furthermore, the
studies provide novel evidence that hypoxia-mediated DNA methylation plays a causal role
in ER-α gene repression and ablation of estrogen-mediated adaptation of uterine arterial
BKca channel activity, resulting in increased uterine arterial myogenic tone in pregnancy [73].
There are significant differences in uterine arterial adaptation to pregnancy between the
long- and short-resident high-altitude populations. The weight of the babies born to Tibetan
residents at high altitude is more than that of those born to Han women living at the same
altitude, which is associated with a higher uterine flow velocity and larger uterine arterial
diameters [1]. The uterine arterial diameters in Andean pregnant women are also most
doubling increased at high altitude whereas there are about half as much increase in Euro-
pean pregnant women [74]. As a result, Andean pregnant women have much higher uterine
blood flows and birth weights of their babies than Europeans at high altitude. However, the
values are the same at low altitude in both Andean and European women, which suggests a
much higher protective effect of Andean ancestry at high altitude. The questions why long-
resident high-altitude populations (such as Tibetan and Andean women) have higher resis-
tant to the adverse effects of high-altitude hypoxia than the short-resident populations (such
as Han and European women) are not fully understood. However, recent reports suggest
that genetic background may play a key role in the altitude-related changes in birth weight
and uterine blood flow [1].




The adaptation of the cardiovascular system to altitude is variable, depending on individual
predisposition, the actual elevation, the rate of ascent, and the duration of exposure. In acute
short-term exposure to HAH, the initial response is increasing sympathetic activity and hyper-
ventilation resulting in increases in systemic vascular resistance, blood pressure, heart rate,
and cardiac output. Pulmonary vasoconstriction leads to pulmonary hypertension. However,
in response to acute HAH, cerebral blood flow (CBF) rises significantly to ensure an adequate
supply of O2 to meet the brain tissues’ large and consistent demand. The sympathetic excita-
tion results from acute HAH, partly through chemoreceptor reflexes and partly through
altered baroreceptor function. In long-term HAH exposure or resident at high altitude, cardio-
vascular system progresses a compensatory adaptation. The cardiovascular system may pro-
mote adaptational changes in cardiovascular structure, remodeling, and functional proteins
through different molecular mechanisms including epigenetic regulatory and/or genetic factor-
mediated mechanisms. However, cardiovasculatures may progress a pathologic adaptation
and develop a maladaptation syndrome known as high-altitude pulmonary edema, cerebral
edema, chronic mountain sickness, pulmonary hypertension, heart failure, and fetal intrauter-
ine growth restriction. In conclusion, cardiovascular system progresses a compensatory and
pathologic adaptation to HAH. Understanding those adaptation processes will help us to
reduce the development of adverse changes and simultaneously preserve the beneficial signs
of the process of adaptation.
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